Michele Spinicci

Dr. Michele Spinicci

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AMAlessio Mazzoni
Alessio Mazzoni
LSLorenzo Salvati
Lorenzo Salvati
LMLaura Maggi
Laura Maggi
MCMANUELA CAPONE
MANUELA CAPONE
AVAnna Vanni
Anna Vanni
Lorenzo CosmiLorenzo Cosmi
Lorenzo Cosmi
BACKGROUND. Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS. We performed a flow cytometric characterization of immune cell subsets from 30 patients with COVID-19 and correlated these data with clinical outcomes. RESULTS. Patients with COVID-19 showed decreased numbers of circulating T, B, and NK cells and exhibited a skewing of CD8+ T cells toward a terminally differentiated/senescent phenotype. In agreement, CD4+ T and CD8+ T, but also NK cells, displayed reduced antiviral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in patients with COVID-19, particularly in those who required intensive care. The latter group of patients also showed increased serum IL-6 levels that inversely correlated to the frequency of granzyme A–expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION. The association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore antiviral mechanisms. FUNDING. This study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (the ex-60% fund and the “Excellence Departments 2018–2022 Project”) derived from Ministero dell’Istruzione, dell’Università e della Ricerca (Italy).

15 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AMAlessio Mazzoni
Alessio Mazzoni
NLNicoletta Di Lauria
Nicoletta Di Lauria
LMLaura Maggi
Laura Maggi
LSLorenzo Salvati
Lorenzo Salvati
AVAnna Vanni
Anna Vanni
FAFrancesco Annunziato
Francesco Annunziato
The characterization of the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of the 2-dose BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (COVID-19–recovered subjects) compared with naive subjects, we evaluated SARS-CoV-2 Spike–specific T and B cell responses, as well as specific IgA, IgG, IgM, and neutralizing antibodies titers in 22 individuals who received the BNT162b2 mRNA COVID-19 vaccine, 11 of whom had a previous history of SARS-CoV-2 infection. Evaluations were performed before vaccination and then weekly until 7 days after second injection. Data obtained clearly showed that one vaccine dose is sufficient to increase both cellular and humoral immune response in COVID-19–recovered subjects without any additional improvement after the second dose. On the contrary, the second dose proved mandatory in naive subjects to further enhance the immune response. These findings were further confirmed at the serological level in a larger cohort of naive (n = 68) and COVID-19–recovered (n = 29) subjects, tested up to 50 days after vaccination. These results question whether a second vaccine injection in COVID-19–recovered subjects is required, and indicate that millions of vaccine doses may be redirected to naive individuals, thus shortening the time to reach herd immunity.

27 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MSMichele Spinicci
Michele Spinicci
LGLucia Graziani
Lucia Graziani
MTMarta Tilli
Marta Tilli
JNJerusalem Nkurunziza
Jerusalem Nkurunziza
IVIacopo Vellere
Iacopo Vellere
Alessandro BartoloniAlessandro Bartoloni
Alessandro Bartoloni
COVID-19 has been associated with a broad range of long-term sequelae, commonly referred to as “long-COVID” or “post-COVID-19” syndrome. Despite an increasing body of literature, long COVID remains poorly characterized. We retrospectively analysed data from electronic medical records of patients admitted to the post-COVID-19 outpatient service of the Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, between June 2020 and June 2021, 4–12 weeks after hospital discharge. A total of 428 patients, 41% women, median age 64 years, underwent a follow-up visit a median 53 days after hospital discharge. Overall, 76% patients reported at least one persistent symptom, including dyspnoea (37%), chronic fatigue (36%), insomnia (16%), visual disorders (13%) and brain fog (13%). Increasing oxygen support (OR 1.4, 95% CI 1.1–1.8), use of immunosuppressants (OR 6.4, 95% CI 1.5–28) and female sex (OR 1.8, 95% CI 1.1–2.9) were associated with a higher risk of long COVID symptoms. Comparison between symptomatic patients infected in the period March–December 2020 (prevalent circulation of wild-type SARS-CoV-2) with those infected in the period January–April 2021 (prevalent circulation of B.1.1.7 Alpha variant) showed a significant modification in the pattern of symptoms belonging to the neurological and cognitive/emotional categories. Our findings confirmed shortness of breath and chronic fatigue as the most frequent long COVID manifestations, while female sex and severe COVID-19 course were the main risk factors for developing lingering symptoms. SARS-CoV-2 variants may induce different long COVID phenotypes, possibly due to changes in cell tropism and differences in viral–host interaction.

1 January 2020 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
MSMichele Spinicci
Michele Spinicci
ABAlessandro Bartoloni
Alessandro Bartoloni
AMAntonia Mantella
Antonia Mantella
LZLorenzo Zammarchi
Lorenzo Zammarchi
GRGian Maria Rossolini
Gian Maria Rossolini
AAAlberto Antonelli
Alberto Antonelli
In the near future, the overlap of COVID-19 and dengue epidemics is a concrete threat in tropical regions.3,4 COVID-19 and dengue share several features of clinical and laboratory presentation, and differential diagnosis should rely on specific diagnostic tests.5 Recently, two cases of false-positive results by rapid diagnostic test (RDT) for dengue in patients with SARS-CoV-2 infection were reported from Singapore.6 If serological cross-reactivity between patients with COVID-19 and dengue will be confirmed, it may result in a high number of misdiagnoses, with dangerous consequences both from the patients and from public health point of view.7

15 March 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AMAlessio Mazzoni
Alessio Mazzoni
AVAnna Vanni
Anna Vanni
MSMichele Spinicci
Michele Spinicci
GLGiulia Lamacchia
Giulia Lamacchia
SKSebleTekle Kiros
SebleTekle Kiros
FAFrancesco Annunziato
Francesco Annunziato
BACKGROUND. Immunization against SARS-CoV-2, the causative agent of COVID-19, occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last. METHODS. We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to 1 year after infection and following mRNA vaccination in naive individuals and individuals recovered from COVID-19 infection. RESULTS. We found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly, especially in naive individuals. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naive individuals, whereas it was ineffective in previously SARS-CoV-2–infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to 1 year following natural infection in a cohort of unvaccinated individuals. CONCLUSION. Short-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. In naive individuals, a booster dose restored optimal anti-spike immunity, whereas the needs for vaccinated individuals who have recovered from COVID-19 have yet to be defined. FUNDING. This study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018–2022), the University of Florence (project RICTD2122), the Italian Ministry of Health (COVID-2020-12371849), and the region of Tuscany (TagSARS CoV 2).

17 March 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
MGMilo Gatti
Milo Gatti
SBSimona Barnini
Simona Barnini
FGFabio Guarracino
Fabio Guarracino
EPEva Maria Maria Parisio
Eva Maria Maria Parisio
MSMichele Spinicci
Michele Spinicci
FGFabrizio Gemmi
Fabrizio Gemmi
Infections associated with orthopaedic implants represent a major health concern characterized by a remarkable incidence of morbidity and mortality. The wide variety of clinical scenarios encountered in the heterogeneous world of infections associated with orthopaedic implants makes the implementation of an optimal and standardized antimicrobial treatment challenging. Antibiotic bone penetration, anti-biofilm activity, long-term safety, and drug choice/dosage regimens favouring outpatient management (i.e., long-acting or oral agents) play a major role in regards to the chronic evolution of these infections. The aim of this multidisciplinary opinion article is to summarize evidence supporting the use of the different anti-staphylococcal agents in terms of microbiological and pharmacological optimization according to bone penetration, anti-biofilm activity, long-term safety, and feasibility for outpatient regimens, and to provide a useful guide for clinicians in the management of patients affected by staphylococcal infections associated with orthopaedic implants Novel long-acting lipoglycopeptides, and particularly dalbavancin, alone or in combination with rifampicin, could represent the best antibiotic choice according to real-world evidence and pharmacokinetic/pharmacodynamic properties. The implementation of a multidisciplinary taskforce and close cooperation between microbiologists and clinicians is crucial for providing the best care in this scenario.